explore -WSS

explore

author：explore 2025-09-28 22:28:58 - browse：267

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Stories you might have missed in 2023: health, science, medicine

hotspot

WSS

At JPM 2024, hospital systems pitch financial strength to investors

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

A look at other Americans who have crossed into North Korea over the years

A strong 6.5

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

entertainment

explore

focus

New air purifier tech could be key to improving indoor air quality

Flagship, Pfizer team up in deal worth up to $7 billion

Wildfire smoke exposes gaps in outdoor worker protections

Fauci's latest grilling in Congress: 9 hours, behind closed doors

United colonoscopy coverage change 'may cost lives,' doctors say

A look at other Americans who have crossed into North Korea over the years

Activists slam private health insurers over coverage restrictions

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

23andMe had bad news about my health. I wish a person had delivered it

Flagship, Pfizer team up in deal worth up to $7 billion

focus

In shift, Texas to cover initial consult for Afghan baby's gene therapy

JPM pitch from hospitals? Revenue streams outside of patient care

BridgeBio heart drug succeeds in pivotal study

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Robert Kennedy Jr.'s presidential campaign attracts GOP

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

hotspot

hotspot

focus

hotspot